Theravance Bioph Stock Price, News & Analysis

Theravance Biopharma (TBPH) announced its financial results for Q4 and full year 2020, highlighting 159% year-over-year sales growth for YUPELRI, now capturing 18.6% of the nebulized COPD market. Despite this growth, total revenue for Q4 decreased by $10.8 million to $18.7 million, with a full year revenue of $71.9 million. Operating loss increased to $76.5 million in Q4. The company is optimistic about ongoing clinical trials, particularly for TD-0903 in COVID-19 patients, and expects significant milestones in 2021, including data releases for ongoing studies. Cash reserves stood at $292.9 million.

Theravance Biopharma (NASDAQ: TBPH) announced its participation in key investor events. Management will engage in a Fireside Chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 24 at 12:00 p.m. ET. Additionally, Richard A. Graham will join the GI/Microbiome Panel at the Cowen 41st Annual Cowen Conference on March 2 at 11:10 a.m. ET. Interested investors can access the webcast via the "Investors" section on Theravance's website, where replays will be available for 30 days.

Theravance Biopharma (NASDAQ: TBPH) will announce its fourth quarter and full year 2020 financial results on February 23, 2021, after market close. A conference call and webcast are scheduled for 5:00 p.m. ET. The company focuses on organ-selective medicines, targeting inflammation and immunology. Notably, it has developed YUPELRI®, an inhalation solution for COPD. The announcement may impact investors keen on financial performance metrics and future growth prospects.

Theravance Biopharma (NASDAQ: TBPH) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:00 p.m. ET. The presentation will focus on the company's commitment to developing organ-selective medicines aimed at treating serious illnesses, particularly in inflammation and immunology. Investors can access the webcast on the company's website and the replay will be available for 30 days. Theravance's research includes the approved YUPELRI® inhalation solution for COPD, showcasing its focus on patient-centered drug development.

Theravance Biopharma (NASDAQ: TBPH) will webcast its presentation at the 3rd Annual Evercore ISI HEALTHCONx Conference on December 1, 2020, at 2:40 p.m. ET. The webcast can be accessed via the Investors section of their website www.theravance.com. Replay will be available for 30 days. The company specializes in organ-selective medicines, focusing on inflammation and immunology, with an aim to improve patient lives. Their notable product includes YUPELRI®, an FDA-approved treatment for chronic obstructive pulmonary disease.

Theravance Biopharma (NASDAQ: TBPH) reported Q3 2020 total revenue of $18.3 million, driven by a significant rise in YUPELRI's sales, which contributed approximately $13.0 million to the revenue. However, the company reported an operating loss of $76.6 million due to increased R&D and SG&A expenses, totaling $67.4 million and $27.5 million respectively. Cash reserves stood at $358.3 million. Despite market challenges from COVID-19, YUPELRI gained market share and brand profitability. The company also anticipates key clinical trial results in Q3 2021 for its pipeline products.

Theravance Biopharma (NASDAQ: TBPH) will announce its third quarter 2020 financial results and provide an update on November 5, 2020, after market close. The conference call will take place at 5:00 p.m. ET. The company focuses on developing organ-selective medicines and has a pipeline aimed at addressing significant patient needs, particularly in inflammation and immunology. They leverage expertise in developing lung-selective medicines like YUPELRI® for treating COPD. Interested parties can access the live call via phone or at their website.

Theravance Biopharma (NASDAQ: TBPH) announced its participation in two upcoming investor conferences. The first is the Morgan Stanley 18th Annual Global Healthcare Conference on September 14, 2020, at 1:30 p.m. ET, followed by the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 9:30 a.m. ET. Webcast presentations will be accessible on the company's website under the "Investors" section, with replays available for at least 30 days. Theravance specializes in organ-selective medicines targeting inflammation and immunology.

Theravance Biopharma (NASDAQ: TBPH) reported Q2 2020 revenue of $15.0 million, down $11.1 million year-over-year, primarily due to decreased collaboration and licensing revenue. Operating loss was $72.2 million, or $55.6 million without share-based compensation. Cash reserves stood at $438.3 million. The company noted a market share increase for YUPELRI despite COVID-19 challenges and aims for it to be cash-flow positive by year-end. Clinical programs for ampreloxetine and TD-1473 were delayed, but progress continues with new COVID-19 related candidate TD-0903.